The examples in this post demonstrate some representative projects and company business development activities in 2023. The scientific part shows the applications of the three main areas of our expertise: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.
We're sharing here the latest company updates. They include a new publication, information about Lund Spring Symposium, and our expected move to new facilities at a new building at Medicon Village.
First-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion. This was made possible by an integrated approach, a fast design-make-test-analyze cycle, and applying structure-based drug design, compound synthesis, and evaluation.
SARomics BIostructures is continuing its expansive phase - new team members, updated our company logotype, expanded our laboratory and office space, and a brand new Protein Shop!